Literature DB >> 15197180

Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine.

Magdalena M Kacprzak1, Juan R Peinado, Manuel E Than, Jon Appel, Stefan Henrich, Gregory Lipkind, Richard A Houghten, Wolfram Bode, Iris Lindberg.   

Abstract

Polyarginine-containing peptides represent potent inhibitors of furin, a mammalian endoprotease that plays an important role in metabolism, activation of pathogenic toxins, and viral proliferation. The therapeutic use of D-polyarginines is especially interesting because they are not cleaved by furin and possess inhibitory potency almost equal to L-polyarginines. In this study we attempted to determine the important elements within polyarginines that contribute to effective inhibition. Structure-function analyses of polyarginine peptides showed that inhibition by polyarginine-containing peptides appeared to depend on the total number of basic charges of the positively charged inhibitors bound to the negatively charged substrate binding pocket; peptide positioning did not appear to be rigorously determined. Screening of L- and D-decapeptide positional scanning combinatorial peptide libraries indicated a preference for basic residues in nearly all positions, similar to previous results with hexapeptide libraries. Length and terminal modification studies showed that the most potent D-polyarginine tested was nona-D-arginine (D9R) amide with a K(i) of 1.3 nm. D9R amide was shown to protect RAW264.7 cells against anthrax toxemia with an IC(50) of 3.7 microm. Because of its high stability, specificity, low toxicity, small molecular weight, and extremely low K(i) against furin, D9R amide or its derivatives may represent promising compounds for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197180     DOI: 10.1074/jbc.M400484200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.

Authors:  Gero L Becker; Yinghui Lu; Kornelia Hardes; Boris Strehlow; Christine Levesque; Iris Lindberg; Kirsten Sandvig; Udo Bakowsky; Robert Day; Wolfgang Garten; Torsten Steinmetzer
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

2.  Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.

Authors:  Feng Li; Irina Chvyrkova; Simon Terzyan; Nancy Wakeham; Robert Turner; Arun K Ghosh; Xuejun C Zhang; Jordan Tang
Journal:  Appl Microbiol Biotechnol       Date:  2012-01-25       Impact factor: 4.813

3.  Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity.

Authors:  Julia M Coppola; Christin A Hamilton; Mahaveer S Bhojani; Martha J Larsen; Brian D Ross; Alnawaz Rehemtulla
Journal:  Anal Biochem       Date:  2007-01-17       Impact factor: 3.365

Review 4.  Proteases for processing proneuropeptides into peptide neurotransmitters and hormones.

Authors:  Vivian Hook; Lydiane Funkelstein; Douglas Lu; Steven Bark; Jill Wegrzyn; Shin-Rong Hwang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

5.  Processing of proaugurin is required to suppress proliferation of tumor cell lines.

Authors:  Akihiko Ozawa; Adam N Lick; Iris Lindberg
Journal:  Mol Endocrinol       Date:  2011-03-24

6.  Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.

Authors:  Bruno Ramos-Molina; Adam N Lick; Elias H Blanco; J Alejandro Posada-Salgado; Karina Martinez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Biochem Pharmacol       Date:  2015-05-21       Impact factor: 5.858

7.  Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin.

Authors:  Kornelia Hardes; Teodora Ivanova; Bastian Thaa; Gerald M McInerney; Tove Irene Klokk; Kirsten Sandvig; Sebastian Künzel; Iris Lindberg; Torsten Steinmetzer
Journal:  ChemMedChem       Date:  2017-04-04       Impact factor: 3.466

8.  Synthetic small-molecule prohormone convertase 2 inhibitors.

Authors:  Dorota Kowalska; Jin Liu; Jon R Appel; Akihiko Ozawa; Adel Nefzi; Robert B Mackin; Richard A Houghten; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2008-12-12       Impact factor: 4.436

9.  Opposite roles of furin and PC5A in N-cadherin processing.

Authors:  Deborah Maret; Mohamad Seyed Sadr; Emad Seyed Sadr; David R Colman; Rolando F Del Maestro; Nabil G Seidah
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

10.  The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures.

Authors:  Bruno P Meloni; Amanda J Craig; Nadia Milech; Richard M Hopkins; Paul M Watt; Neville W Knuckey
Journal:  Cell Mol Neurobiol       Date:  2013-11-09       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.